Integra LifeSciences raises profit guidance as management transition takes hold

Integra LifeSciences (NASDAQ:IART) signaled a turning point in its operational recovery today, raising its full-year profit guidance even as it recorded a GAAP loss during a quarter defined by significant leadership changes and supply chain stabilization.

The Princeton, New Jersey-based medical technology company reported first-quarter revenue of $391.9 million, representing a 2.4% increase on a reported basis and a 1.3% organic gain.

While the company posted a GAAP net loss per share of $0.06, its adjusted performance remained resilient.

Adjusted earnings per share (EPS) came in at $0.54, supported by an adjusted EBITDA of $76.2 million, or 19.4% of total revenue.

The quarter was marked by a major reshuffling of the executive suite.

Stuart Essig has stepped into the CEO role, and Michael McBreen has been appointed Chief Commercial Officer.

The new leadership team is tasked with restoring manufacturing consistency across Integra’s tissue technologies and neurosurgery product lines following production hurdles in 2025.

Reflecting this confidence, Integra raised its full-year 2026 adjusted EPS guidance to a range of $2.40 to $2.50, up from previous estimates.

The company reaffirmed its revenue guidance for the year at $1.662 billion to $1.702 billion.